Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

901.P1.97 Health Services and Outcomes Research Poster I

Saturday, December 6, 2008: 5:30 PM-7:30 PM
Hall A (Moscone Center)
Study Drug and Visit Adherence: Data from the BABY HUG Trial

Courtney D. Thornburg, MD, MS1, Zora R. Rogers, MD2, Winfred Wang, MD3, Michael Jeng, MD4, Sohail R Rana, MD5*, Rathi V. Iyer, MD6*, Lane Faughnan, RN, BSN, CCRP3*, Jennifer Marshall, RN, ADN, CLNC2*, Leann Hassen, MPH7*, Roy McDonald, MPH6*, Renee C. Rees, PhD8* and for The BABY HUG Investigators8*

1Duke University Medical Center, Durham, NC
2Children's Medical Center of Dallas/UTSW, Dallas, TX
3St. Jude Children's Research Hospital, Memphis, TN
4Stanford Univ. School of Medicine, Palo Alto, CA
5Howard University Hospital, Washington DC, DC
6University of Mississippi Medical Center, Jackson, MS
7Aflac Cancer Center and Blood Disorders Service, Atlanta, GA
8Clinical Trials & Surveys, Corp., Baltimore, MD

National Hopitalization Rates for Sickle Cell Disease in the Hydroxyurea Era

Maureen Okam, MD and Stuart Lipsitz, D., Sc.*

Harvard Medical School, Brigham and Women's Hosp., Boston, MA

The Prevalence of Immune Thrombocytopenic Purpura (ITP)

Deirdra Terrell, PhD1, Laura A Beebe, PhD1*, James George, MD1, Barbara R Neas, PhD1*, Sara K. Vesely, PhD1 and Jodi Segal, M.D.2*

1University of Oklahoma Health Sciences Center, Oklahoma City, OK
2Medicine, Johns Hopkins Medical Institutions, Baltimore

Anticoagulant Self-Management using near Patient Testing and Decision Support Software Provided via An Internet Website Improved Anticoagulant control in Patients on Long-Term Warfarin

Paul L Harper, MD, FRCP, FRACP* and Daryl Pollock*

Clinical Haematology, Palmerston North Hospital, Palmerston North, New Zealand

Supplemental Use of Inferior Vena Cava Filters: A Review of An Institutional Experience

Parminder Singh, MD, MBBS1*, Robert G. Lerner, MD2, Tarun Chugh2*, Hoang Lai2* and Wilbert S Aronov2*

1Internal Medicine, Westchester Medical Center, North White Plains, NY
2New York Medical College, Valhalla, NY

A Cost-Benefit Analysis of D-Dimer Measurement by a High Sensitivity Asay, as the First Step to Rule out a Venous Thromboembolism Suspected Episode, Independently of Pretest Clinical Probability

Francesc J Casals, MD, PhD1*, Davide Bernaudo, MD1*, Jaume Villalta, MD2*, Naila Lozano, RN3* and Gines Escolar, MD, PhD4

1Hemotherapy-Hemostase, Thromboembolism Unit (UFMATE), Hospital Clinic, Barcelona, Spain
2Internal Medicine, Hospital Clinic, Barcelona, Spain
3Thromboembolism Unit (UFMATE), Fundacio Clinic, Barcelona, Spain
4Hospital Clinic, Barcelona, Spain

Mandatory Clinical Pre-Test Probability Assessment Combined with D-Dimer Testing in Outpatients Did Not Result in a Reduction in Radiological Test Utilization for Investigation of VTE

Sarah Ingber, MD1*, Rita Selby, MD1, Jacques Lee, MD2*, William Geerts, MD1* and Elena Brnjac, MLT3*

1Medicine, Sunnybrook Health Sciences Center, Toronto, ON, Canada
2Emergency Medicine, Sunnybrook Health Sciences Center
3Clinical Pathology, Sunnybrook Health Sciences Center

Adherence to Guidelines for Monitoring for Heparin-Induced Thrombocytopenia in Patients Treated with Low Molecular Weight Heparin

Maarten ten Berg1*, Patricia Van den Bemt1*, Albert Huisman, PhD2, Fred Schobben1*, Toine Egberts1* and Wouter Van Solinge1*

1Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht, Netherlands
2Clinical Chem. & Haem., G.03.550, University Medical Center Utrecht, Utrecht, Netherlands

Oral Warfarin Remains An Effective Treatment Option in the Extended Prophylaxis of VTE for Patients with Cancer: The Effectiveness of the CancerCare Manitoba  (CCMB) Anticoagulation Clinic (ACC)

Vi Dao, MD1, David Szwajcer, MD1*, Rick Prayag, PharmD2* and Don Houston, MD, PhD1*

1Hematology, CancerCare Manitoba, Winnipeg, MB, Canada
2CancerCare Manitoba, Winnipeg, MB, Canada

2008 Guidelines for the Treatment of Venous Thromboembolism in Cancer Patients: Report from the French Working Group

Dominique Farge1*, Lise Bosquet2*, Diana Kassab Chahmi3*, Francis Cajfinger4*, Hélène Desmurs-Clavel5*, Eric Desruennes6*, Marie Cécile Douard7*, Antoine Elias8*, Ismaïl Elalamy9*, Claire Grange10*, Hamid Hocini11*, Irène Kriegel12*, Hérvé Lévesque13*, Isabelle Mahé14*, Guy Meyer15*, Patrick Mismetti16*, Michel Pavic17*, Isabelle Quéré18*, Jean Marc Renaudin1*, Marie Loraine Scrobohaci19*, Gregoire Le Gal, MD20* and Philippe Debourdeau17*

1Internal medicine and vascular patholgy, Saint Louis Hopsital, Paris, France
2Sor, Institut National du Cancer, Boulogne Billancourt Cedex, France
3Sor, Institut National u Cancer, Boulogne Billancourt Cedex, France
4Oncology, La Pitié Hospital, Paris, France
5Internal medicine and vascular pathology, Edouard Herriot Hospital, Lyon, France
6Anesthesiology, Institut Gustave Roussy, Villejuif, France
7Anesthsiology, Saint Louis Hopsital, Paris, France
8Vascular medicine, Font Pré Hospital, Toulon, France
9Haemostasis, Tenon Hospital, Paris, France
10Internal medicine and vascular pathology, Lyon Sud Hospital, Pierre Bénite, France
11Oncology, Saint Louis Hospital, Paris, France
12Anesthesiology, Curie Institute, Paris, France
13Internal Medicine and vascular pathology, Bois Guillaume Hospital, Bois Guillaume, France
14Internal medicine and vascular pathology, Louis Mourier Hospital, Colombes, France
15Pneumology, Pompidou European Hospital, Paris, France
16Vascular pathology, Bellevue Hospital, Saint Etienne, France
17Oncology hematology, Desgenettes Military Hospital, Lyon, France
18Vascular pathology, Saint Eloi Hospital, Montpellier, France
19Haemostasis, Saint Louis Hospital, Paris, France
20Brest University Hospital, Brest, France

Economic Outcomes in Patients at Risk for Venous Thromboembolism Receiving Appropriate Enoxaparin or Unfractionated Heparin Prophylaxis

Alpesh Amin, MD, MBA, FACP1*, Jay Lin, PhD, MBA2*, Greg Lenhart3* and Kathy Schulman3*

1Division of General Internal Medicine, Department of Medicine, University of California, Irvine, Associate Clinical Professor, Orange, CA
2sanofi-aventis US, Inc, Bridgewater, NJ
3Thomson Reuters, Cambridge, MA

Are Hospitals Following Guidelines for VTE Prevention? the Veneous Thromoembolism Study to Assess the Rate of Thromboprophylaxis

Alpesh Amin, MD, MBA, FACP1*, Alex Spyropoulos, MD, FACP, FCCP2*, Paul Dobesh, PharmD, FCCP, BCPS3*, Andrew Shorr, MD4*, Mohamed Hussein, Ms.C.S., M.S.P.H, Ph.D.5*, Essy Mozaffari, PharmD, MPH6* and Joshua Benner, PharmD, ScD5*

1Division of General Internal Medicine, Department of Medicine,, University of California, Irvine, Orange, CA
2Lovelace Medical Center, Clinical Thrombosis Center, Albuquerque, NM
3Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE
4Department of Medicine, Pulmonary & Critical Care Medicine Service, Washington Hospital Center, Washington, DC
5Health Economics and Outcomes Research, IMS Health, Falls Church, VA
6Sanofi-Aventis, Brigewater, NJ

Appropriate VTE Prophylaxis Is Associated with Lower Direct Medical Costs among Medical and Surgical Patients in the United States

Alpesh Amin, MD, MBA, FACP1*, Mohamed Hussein, Ms.C.S., M.S.P.H, Ph.D.2*, David Battleman, MD2*, Jay Lin, PhD, MBA3*, Steve Stemkowski, MHA4* and Geno J Merli, MD5*

1Division of General Internal Medicine, Department of Medicine, University of California, Irvine, Associate Clinical Professor, Orange, CA
2Health Economics and Outcomes Research, IMS Health, Falls Church, VA
3sanofi-aventis US, Inc., Bridgewater, NJ
4Premier Inc, Charlotte, NC
5Thomas Jefferson University Hospital, Philadelphia, PA

Improving Compliance with Guidelines for Venous Thromboembolism (VTE) Prophylaxis Significantly Reduces VTE Events

Manmeet S Ahluwalia, MD1*, Kimberly Klein, RN, RPA-C2*, Boris W Kuvshinoff, MD3*, Francisco J. Hernandez-Ilizaliturri, MD4, Gregory Wilding, PhD1*, Judy L. Smith, MD, MS5* and Minoo Battiwalla, MD6

1Medicine, Roswell Park Cancer Institute, Buffalo, NY
2Roswell Park Cancer Institute, Buffalo
3Surgery, Roswell Park Cancer Institute, Buffalo
4Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY
5Surgery, Roswell Park Cancer Institute, Buffalo, NY
6Roswell Park Cancer Institute, Buffalo, NY

Rivaroxaban for Prevention of Venous Thromboembolism after Total Knee Replacement: Impact on Healthcare Costs Based on the RECORD4 Study

Louis Kwong1*, Nishan Sengupta2* and Michael Lees3*

1Harbor-UCLA Medical Center, Torrance, CA
2Johnson & Johnson, CA
3Bayer plc, Uxbridge, ARRAY(0xc62f6dc)

Will Rivaroxaban Be Cost-Effective for Prevention of Venous Thromboembolism after Total Hip Replacement in US Patients?

Louis Kwong1*, Alexander Diamantopoulos2*, Fiona Forster2*, Nishan Sengupta3* and Michael Lees4*

1Harbor-UCLA Medical Center, Torrance, CA
2IMS Health, London, United Kingdom
3Johnson & Johnson, CA
4Bayer plc, Uxbridge, ARRAY(0xc62f6dc)

Cost-Effectiveness of Rivaroxaban as VTE Prophylaxis after Total Hip Replacement in Canada

Philip Wells, MD, FRCPC, MSc1, Alexander Diamantopoulos2*, Fiona Forster2*, Michael Lees3* and Heather McDonald4*

1Ottawa Hospital Civic Site, Ottawa, ON, Canada
2IMS Health, London, United Kingdom
3Bayer plc, Uxbridge, ARRAY(0xc62f6dc)
4Bayer Inc, Toronta, Canada

Indirect Comparisons of Rivaroxaban Versus Alternative Prophylaxes for the Prevention of VTE in Patients Undergoing Total Knee Replacement

Alexander Diamantopoulos1*, Corrine LeReun2*, Farhat Rasul1*, Michael Lees3*, Maria Kubin4* and Philip Wells, MD, FRCPC, MSc5

1IMS Health, London, United Kingdom
2Independent statistician, Ireland
3Bayer plc, Uxbridge, ARRAY(0xc62f6dc)
4Bayer HealthCare AG, Wuppertal, Germany
5Ottawa Hospital Civic Site, Ottawa, ON, Canada

The Cost of HIT-Safe Anticoagulant Use at a Tertiary Care, Adult, Academic Hospital

Natasha Nanwa, MSc1*, Nicole Mittmann, MSc, PhD2*, Sandra Knowles, BScPhm3*, Claudia Bucci, BScPhm, PharmD3*, Rita Selby, MBBS, FRCPC1, Neil Shear, MD, FRCPC2*, Scott Walker, MScPhm3* and William H. Geerts, MD, FRCPC4

1Sunnybrook Health Sciences Centre, Toronto, ON, Canada
2Division of Clinical Pharmacology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
3Pharmacy, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
4Sunnybrook Health Science Centre, Toronto, ON, Canada

A Cost-Effectiveness Analysis of Coagulation Testing Prior to Tonsillectomy and Adenoidectomy in Children

James D. Cooper, MD1, Kenneth J Smith, MD, MS2* and Arthur Kim Ritchey, MD1

1Department of Pediatrics, Division of Hematology/Oncology, Children's Hospital of Pittsburgh, Pittsburgh, PA
2Department of Medicine, Section of Decision Sciences and Clinical Systems Modeling, University of Pittsburgh, Pittsburgh, PA

Cost Effectiveness Strategy to Predict Postoperative Bleeding in Von Willebrand Disease

Daniel Delitto, BS1*, Margaret V. Ragni, MD, MPH2 and Kenneth J Smith, MD, MS3*

1Medicine, Division Hematology, Oncology, University of Pittsburgh and Hemophilia Center of Western PA, Pittsburgh, PA
2Department of Medicine, Division Hematology/Oncology, University of Pittsburgh and Hemophilia Center of Western PA, Pittsburgh, PA
3Department of Medicine, Section of Decision Sciences and Clinical Systems Modeling, University of Pittsburgh, Pittsburgh, PA

Comparison of Epoetin Alfa and Darbepoetin Alfa Dosing and Costs in an Inpatient Population with Myelodysplastic Syndromes

Marie-Hélène Lafeuille, BA1*, Francis Vekeman, MA1*, Robert A. Bailey, MD2*, R. Scott McKenzie, MD2 and Patrick Lefebvre, MA1*

1Groupe d'Analyse, Ltée, Montréal, QC, Canada
2Centocor Ortho Biotech Services, LLC, Bridgewater, NJ

The Impact of Methodological Approach on Cost Findings in Comparison of Epoetin Alfa with Darbepoetin Alfa

Xue Song1*, Stacey R Long1*, William D Marder1*, Sean D Sullivan2* and Joel Kallich, PhD3

1Thomson Reuters, Cambridge, MA
2University of Washington, Seattle, WA
3Amgen, Thousand Oaks, CA

Effect of New Institutional Algorithm for Chemotherapy Induced Anemia (CIA) on Erythropoiesis-Stimulating Agent Treatment Patterns and Costs in Lymphoma Patients

Aditya D. Raju, M.S.1*, Lal S. Lal, PhD2*, Lesley-Ann Miller, PhD2*, Hua Chen, PhD1* and Sujit S Sansgiry, PhD1*

1Department of Clinical Sciences and Administration, University of Houston College of Pharmacy, Houston, TX
2Department of Drug Use Policy and Pharmacoeconomics, University of Texas M. D. Anderson Cancer Center, Houston, TX

Impact of Safety Concerns of Erythropoiesis-Stimulating Agents (ESAs) and Regulatory Changes on the Use of ESAs and Red Blood Cell (RBC) Transfusions at a Comprehensive Cancer Center

Saroj Vadhan-Raj, UTMD1, Victoria E. Hawkins, MPH, DRPH, RN2*, Xiao Zhou, MD, PHD3*, Kurt Sizer, MD4, Lincy S. Lal, PHD, PHARMD, RPH5*, Joyce Roquemore, MBA, CPHQ6*, Rebecca B. Arbuckle, MS, RPH7*, Robert S. Benjamin, MD, BA8* and Benjamin Lichtiger, MD, PhD9

1Cytokines & Supportive Oncology, M.D. Anderson Cancer Center, Houston, TX
2Cytokines and Supportive Oncology, UTMD Anderson Cancer Center, Houston
3Cytokines & Supportive Oncology, UTMD Anderson Cancer Center, Houston, TX
4UTMD Anderson Cancer Center, Houston, TX
5Pharmacoeconomics Res Spec, UTMD Anderson Cancer Center, Houston
6Quality Management/Patient Safety, Banner Estrella Medical Center, Phoenix
7Pharmacy Drug Use Policy & PECON, UTMD Anderson Cancer Center, Houston
8Sarcoma Medical Oncology, UTMD Anderson Cancer Center, Houston
9M.D. Anderson Cancer Center, Houston, TX

Pre- vs. Post-National Coverage Determination (NCD) Blood Utilization and Hemoglobin Values among Medicare Patients Treated with Erythropoietic-Stimulating Agents (ESAs) for Chemotherapy-Induced Anemia (CIA)

Tanya Burton, PhD1*, Kay Larholt, ScD1*, Elizabeth Apgar, MPH1*, Chris Pashos, PhD1*, Brahim Bookhart, MBA, MPH2*, Mitra Corral, MS, MPH2*, Catherine Tak Piech, MBA2* and R. Scott McKenzie, MD2

1Abt Bio-Pharma Solutions, Inc., Lexington, MA
2Centocor Ortho Biotech Services, LLC, Bridgewater, NJ

Analysis of Increased Blood Transfusions in U.S. Hospitals, 1997 - 2006

Chaya T. Merrill, MPH, DrPH, (c)1*, Jeffery L Miller, MD2 and Claudia Steiner, MD, MPH3*

1Heatlh Services Research, Thomson Reuters/Agency for Healthcare Research and Quality, Washington, DC
2Molecular Medicine Branch, NIDDK, NIH, Bethesda, MD
3Agency for Healthcare Research and Quality, Rockville, MD

Blood, Esa's and Costs

Dialina Brilhante, MD1*, Ana Macedo1* and Ana Harfouche2*

1Serviço de Imuno hemoterapia, Departamento de Hematologia, Instituto Português de Oncologia Lisboa Francisco Gentil, Lisboa, Portugal
2Administração Hospitalar, Instituto Português de Oncologia Lisboa Francisco Gentil, Lisboa, Portugal

Patient-Reported Fatigue Scores in Cancer Patients with Chemotherapy-Induced Anemia Treated with Erythropoietic-Stimulating Agents (ESAs)

Tanya Burton, PhD1*, David Hoaglin, PhD1*, Kay Larholt, ScD1*, Elizabeth Apgar, MPH1*, Chris Pashos, PhD1*, Brahim Bookhart, MBA, MPH2*, Mitra Corral, MS, MPH2*, Catherine Tak Piech, MBA2* and R. Scott McKenzie, MD2

1Abt Bio-Pharma Solutions, Inc., Lexington, MA
2Centocor Ortho Biotech Services, LLC, Bridgewater, NJ

Erythropoiesis Stimulating Agents (ESA) for the Treatment of Chemotherapy Induced Anemia in Patients with Hemoglobin Levels (Hb) <11g/Dl- a Systematic Review and Meta-Analysis

Luciano Paladini1*, Otavio Clark, MD, PhD1*, Luciana Clark1*, Tobias Engel2* and Eneas Faleiros, MD1*

1Evidencias Medicas, Campinas, Brazil
2Evidencias Medicas

Satisfaction and Adherence Significantly Improves in Patients with β-Thalassemia and Myelodysplastic Syndromes Treated with Deferasirox (Exjade®)

John B Porter1*, Donald Bowden2*, Arnold Ganser3*, Gabor Domokos4*, Diana Rofail5*, Jean-François Baladi6* and Maria Domenica Cappellini7

1University College London, London, United Kingdom
2Monash Medical Centre, Melbourne, Australia
3Medizinische Hochschule Hannover, Hannover, Germany
4Novartis, Basel, Switzerland
5Mapi Values, Cheshire, United Kingdom
6Novartis, East Hanover, NJ
7Universitá di Milano, Policlinico Foundation IRCCS, Milan, Italy

Improved Health-Related Quality of Life in Patients with Hematological Disorders Receiving Deferasirox (Exjade®)

John B Porter1*, Donald Bowden2*, Arnold Ganser3*, Gabor Domokos4*, Adam Gater5*, Jean-François Baladi6* and Maria Domenica Cappellini7

1University College London, London, United Kingdom
2Monash Medical Centre, Melbourne, Australia
3Medizinische Hochschule Hannover, Hannover, Germany
4Novartis, Basel, Switzerland
5Mapi Values, Cheshire, United Kingdom
6Novartis, East Hanover, NJ
7Universitá di Milano, Policlinico Foundation IRCCS, Milan, Italy

Impact of Management of Iron Overload in Patients with Myelodsplastic Syndromes

Duygu Bozkaya1*, Kristen Migliaccio-Walle1* and Jean-Franςois Baladi2*

1United Biosource Corporation, Lexington, MA
2Novartis, East Hanover, NJ

Prospective Multicenter Study for Evaluating Cognitive Disorders in Hematology-Oncology: A Pilot Study of 118 Patients

Jean François Rossi1*, Laurence Laurier III2*, Jean-Louis Misset3*, Dominique Spaeth4*, F. Uwer5*, Pierre Soubeyran6*, Remy Largiller7*, Jean-Philippe Metges8*, Jean-Yves Blay9*, Michel Attal10*, Thierry Facon11*, Olivier Hermine12*, Roland Bugat13*, Jean-Philippe Spano14*, Laurent Cals15*, Hervé Cure16*, Dan Atlan17* and Mario Gjoklaj17*

1Hematology-Oncology, INSERM U847 University of Montpellier, Montpellier, France
2Neurology, Hopital Roger Salengro, Lille, France
3Hopital Saint Louis, Paris, France
4Medical Oncology Center, Nancy, France
5Radiotherapy, Alexis Vautrin, Vandoeuvre les Nancy, France
6Cancerology Service, Bergonie Institute, Bordeaux, France
7Medical Oncology Center, Antoine Lassagne center, Nice, France
8Oncology Center, CHU Brest, Brest, France
9Oncology-Hematology, Eduard Herriot Hospital, Lyon, France
10Hematology, Purpan Hospital, Toulouse, France
11Claude Huriez Hospital, Lille, France
12Hematology, Necker Hospital, Paris, France
13Claudius Ragaud Institute, Toulouse, France
14Medical Onclology Service, Pitié-Salpetriere Hospital, Paris, France
15Oncology-Hematpology Service, CHI Toulon, Toulon, France
16Jean-Perrin Center, Clermont Ferrand, France
17Medical Affairs, Janssen Cilag France, Issy-les-Moulineaux, France

Comprehensive Geriatric Assessment (CGA) in Elderly Patients with Hematological Neoplasia: CGA and Not Age Predicts Mortality - Results from in-GHO®-Registry

Ulrich Wedding1*, Friedemann Honecker2*, Klaus Rettig3*, Susanne Huschens4* and Carsten Bokemeyer5*

1Geriatrics, Universitätsklinikum Jena, Jena, Germany
2Hematology and Oncology, Universitätsklinikum Eppendorf, Hamburg, Germany
3Gesellschaft für Evaluation und Qualitätssicherung in der Medizin mbH, Meerbusch, Germany
4Division of Janssen-Cilag GmbH, Ortho Biotech, Neuss, Germany
5University Hospital Eppendorf, Hamburg, Germany

Comprehensiveness of Quality of Life Instruments in Capturing Concerns Related to Chemotherapy-Induced Neutropenia

Nina Lathia, MSc1*, Pierre Isogai, BSc2*, Nicole Mittmann, PhD3*, Carlo DeAngelis, PharmD4*, Matthew Cheung2*, Knowles Sandra4*, Eugenia Piliotis2*, Neil Shear2* and Scott Walker4*

1Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada
2Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada
3Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
4Pharmacy, Sunnybrook Health Sciences Centre, Toronto, Canada

Final Risk Prediction Model for Neutropenic Complications in Patients Receiving Cancer Chemotherapy

Gary H. Lyman, MD, MPH1, Jeffrey Crawford, MD1, Nicole M. Kuderer, MD1, Debra Wolff, MS, PCNP1*, Eva Culakova, PhD, MS1, Marek S. Poniewierski, MD, MS1 and David C. Dale, MD2

1Duke University, Durham, NC
2University of Washington, Seattle, WA

Analysis of Efficacy, Safety and Costs of Systemic Antifungal Agents in 159 Consecutive High-Risk Cancer Patients for the Establishment of Standardized Guidelines

Werner Neubauer1*, Martina Kleber, MD1, Alf Zerweck, MD1*, Veronique Thierry, MD1*, Alexandra Goebel, PhD2*, Beate Lubrich, PhD2*, Hartmut Bertz, MD1* and Monika Engelhardt, MD1

1Hematology and Oncology, University of Freiburg, Freiburg, Germany
2Hospital Pharmacy, University of Freiburg, Freiburg, Germany

Cost-Effectiveness of Antifungal Strategies in High-Risk Neutropenic Patients

Michael Schwarzinger1*, Sylvain Baillot2*, Celine Beauchamp3*, Sebastien Maury4*, C.écile Pautas, MD5*, Anne Vekhoff6*, Hassan Farhat7*, Felipe Suarez8*, Francois Hemery4*, Mathieu Kuentz, MD9* and Catherine Cordonnier, MD10

1u707, INSERM, Paris, France
2Institut Gustave Roussy, Villejuif, France
3CHU Rennes, Rennes, France
4Henri Mondor hospital, Creteil, France
5Hematology, Henri Mondor University Hospital, 94000 Creteil, France
6Hotel Dieu hospital, Paris, France
7CH Versailles, Versailles, France
8Hématologie clinique, Hôpital Necker, Paris, France
9Hopital Henri-Mondor - SFGMTC, Paris, France
10Hematologie Clinique, Hopital Henri Mondor, Creteil, France

Preventing Infections in Cancer Patients: Antibiotics, Hematopoetic Growth Factors or Both? a Network Analysis

Christine Herbst, MD, MPH1*, Frauke Naumann, Dr.1*, Olaf Herbst, Dr.2*, Julia Bohlius, Dr.1*, Peter Jüni, PD, Dr.3* and Andreas Engert, Prof., Dr.4

1Cochrane Haematological Malignancies Group, First Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany
2Aerospace Engineering, Technische Universiteit Delft, Netherlands
3Institute of Social and Preventive Medicine, Division of Clinical Epidemiology and Biostatistics, University of Bern, Bern, Switzerland
4First department of Internal Medicine, University of Cologne, Cologne, Germany

Compliance with Immunizations in Splenectomized Individuals: A Study of the Splenectomized Hereditary Spherocytosis Population

Rachael F. Grace, MD*, Rachel E. Mednick* and Ellis J. Neufeld, MD, PhD

Hematology/Oncology, Children's Hospital Boston, Dana Farber Cancer Institute, Boston, MA

Assessment of Nutrition Status in Children with Leukemia: A Study from a Developing Country

Soma Mukhopadhyay, Scientist1*, Tusi Dutta, Clinical, Nutritionist1*, Sonali Dey, Oncology, Nurse1*, Somnath Datta, Resident, Medical, Officer1* and Ashis Mukhopadhyay, Haemato, Oncologist2

1Netaji Subhas Chandra Bose Cancer Research Institute, Kolkata, India
2Haemato Oncology, Netaji Subhas Chandra Bose Cancer Research Institute, Kolkata, India

Participation in a Clinical Trial Does Not Impact Outcome in Pediatric Acute Lymphoblastic Leukemia

Carl Koschmann, MD1*, Doug S Hawkins, MD2* and Blythe Thomson, MD3

1Pediatrics, University of Washington, Seattle, WA
2Hematology/Oncology, Seattle Childrens Hospital Regional Medical Center, Seattle, WA
3Children's Hosp. & Regional Med. Ctr., Seattle, WA

Validation of the Korean Version of the Minneapolis-Manchester Quality of Life Instrument for Childhood Cancer Survivors

Hyeon Jin Park1*, Yoon Yi Kim2*, Young Ae Kim3*, Young Ho Yun3*, Byung Ho Nam4*, Ha Kyoung Kim5*, Smita Bhatia6, Young Joo Kwon7*, Soo Hyun Lee7*, Byung-Kiu Park1*, Thad. T Ghim8*, Hyoung Jin Kang9, Hee Young Shin9* and Hyo Seop Ahn9*

1Pediatric Oncology Clinic, National Cancer Center, Goyang, South Korea
2Korea Childhood Leukemia Foundation
3Division of Cancer Control, Research Institute for National Cancer Control and Evaluation, National Cancer Center, Goyang-si, South Korea
4Cancer Registration and Biostatistics Branch, National Cancer Center, Goyang-si, South Korea
5Psycho Oncology Clinic, National Cancer Center, Goyang, South Korea
6City of Hope National Medical Center, Duarte, CA
7Pediatric Oncology Clinic, Specific Organs Cancer Center, National Cancer Center, Goyang-si, South Korea
8Department of Pediatrics, Korea Cancer Center Hospital, Goyang
9Department of Pediatrics, Seoul National University College of Medicine, Seoul, South Korea

A Psychometric Analysis of Parents of Children with Leukemia

Huyong Zheng, MD, PhD1*, Xinyi Wu, RN1*, Ruidong Zhang, MD, PhD1*, Liqin Huo, PhD2*, Huaqing Liu, MD3*, Xiumei Wang, RN1*, Yamei Hu, MD1*, Xiaoyan Lu, MD1* and Huifang Gao, MD1*

1Hematology Oncology Center, Beijing Children' Hospital, Capital Medical University, Beijing, China
2Psycology, Medical School of Beijing University, Beijing, China
3Psycology, Beijing Huilongguan Hospital, Beijing

Lymphoma and Whole Body CT Scan Mortality Risk

Pareen J. Shenoy, MBBS, MPH*, Tulasi Gude*, Rajni Sinha, MD* and Christopher R. Flowers, MD

Winship Cancer Institute, Emory University, Atlanta, GA

*signifies non-member of ASH